Potent_NN
and_CC
stable_JJ
attenuation_NN
of_IN
live-HIV-1_NN
by_IN
gain_NN
of_IN
a_DT
proteolysis-resistant_JJ
inhibitor_NN
of_IN
NF-kappaB_NN
-LRB-_-LRB-
IkappaB-alphaS32_CD
\/_:
36A_CD
-RRB-_-RRB-
and_CC
the_DT
implications_NNS
for_IN
vaccine_NN
development_NN
._.

Live-attenuated_JJ
human_JJ
immunodeficiency_NN
viruses_NNS
-LRB-_-LRB-
HIVs_NN
-RRB-_-RRB-
are_VBP
candidates_NNS
for_IN
Acquired_VBN
Immunodeficiency_NN
Syndrome_NN
-LRB-_-LRB-
AIDS_NN
-RRB-_-RRB-
vaccine_NN
._.

Based_VBN
on_IN
the_DT
simian_JJ
immunodeficiency_NN
virus_NN
-LRB-_-LRB-
SIV_NN
-RRB-_-RRB-
model_NN
for_IN
AIDS_NN
,_,
loss-of-function_NN
-LRB-_-LRB-
e.g._FW
deletion_NN
of_IN
accessory_JJ
genes_NNS
such_JJ
as_IN
nef_NN
-RRB-_-RRB-
has_VBZ
been_VBN
forwarded_VBN
as_IN
a_DT
primary_JJ
approach_NN
for_IN
creating_VBG
enfeebled_JJ
,_,
but_CC
replication-competent_JJ
,_,
HIV-1_NN
\/_:
SIV_NN
._.

Regrettably_RB
,_,
recent_JJ
evidence_NN
suggests_VBZ
that_IN
loss-of-function_NN
alone_RB
is_VBZ
not_RB
always_RB
sufficient_JJ
to_TO
prevent_VB
the_DT
emergence_NN
of_IN
virulent_JJ
mutants_NNS
._.

New_JJ
strategies_NNS
that_WDT
attenuate_VBP
via_IN
mechanisms_NNS
distinct_JJ
from_IN
loss-of-function_NN
are_VBP
needed_VBN
for_IN
enhancing_VBG
the_DT
safety_NN
phenotype_NN
of_IN
viral_JJ
genome_NN
._.

Here_RB
,_,
we_PRP
propose_VBP
gain-of-function_NN
to_TO
be_VB
used_VBN
simultaneously_RB
with_IN
loss-of-function_NN
as_IN
a_DT
novel_JJ
approach_NN
for_IN
attenuating_VBG
HIV-1_NN
._.

We_PRP
have_VBP
constructed_VBN
an_DT
HIV-1_NN
genome_NN
carrying_VBG
the_DT
cDNA_NN
of_IN
a_DT
proteolysis-resistant_JJ
nuclear_JJ
factor-kappaB_NN
inhibitor_NN
-LRB-_-LRB-
IkappaB-alphaS32_CD
\/_:
36A_CD
-RRB-_-RRB-
in_IN
the_DT
nef_NN
region_NN
._.

HIV-1_NN
expressing_VBG
IkappaB-alphaS32_NN
\/_:
36A_CD
down-regulates_VBZ
viral_JJ
expression_NN
and_CC
is_VBZ
highly_RB
attenuated_VBN
in_IN
both_CC
Jurkat_NN
and_CC
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
._.

We_PRP
provide_VBP
formal_JJ
proof_NN
that_IN
the_DT
phenotypic_JJ
and_CC
attenuating_NN
characteristics_NNS
of_IN
IkappaB-alphaS32_NN
\/_:
36A_CD
permit_VBP
its_PRP$
stable_JJ
maintenance_NN
in_IN
a_DT
live_JJ
,_,
replicating_VBG
HIV-1_NN
despite_IN
180_CD
days_NNS
of_IN
forced_JJ
ex_FW
vivo_FW
passaging_NN
in_IN
tissue_NN
culture_NN
._.

As_IN
compared_VBN
with_IN
other_JJ
open-reading_JJ
frames_NNS
embedded_JJ
into_IN
HIV\/SIV_NN
genome_NN
,_,
this_DT
degree_NN
of_IN
stability_NN
is_VBZ
unprecedented_JJ
._.

Thus_RB
,_,
IkappaB-alphaS32_NN
\/_:
36A_CD
offers_VBZ
proof-of-principle_NN
that_IN
artifactually_RB
gained_VBN
functions_NNS
,_,
when_WRB
used_VBN
to_TO
attenuate_VB
the_DT
replication_NN
of_IN
live_JJ
HIV-1_NN
,_,
can_MD
be_VB
stable_JJ
._.

These_DT
findings_NNS
illustrate_VBP
gain-of-function_NN
as_IN
a_DT
feasible_JJ
strategy_NN
for_IN
developing_VBG
safer_JJR
live-attenuated_JJ
HIVs_NNS
to_TO
be_VB
tested_VBN
as_IN
candidates_NNS
for_IN
AIDS_NN
vaccine_NN
._.

